<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260707070089N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-11-10</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Two Antibiotic Regimens for the Prevention of Infection Following Uterine Surgery</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effectiveness of metronidazole plus cefazolin compared to cefazolin alone in reducing surgical siteinfections in women undergoing abdominal hysterectomy and myomectomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-12-24</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>110</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/92088</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Health service research, Randomization description: Randomization Procedure

Block randomization will be used in this study. Participants will be assigned in blocks of four, with two participants allocated to the intervention group and two to the control group within each block. The allocation sequence within each block will be determined randomly (e.g., AABB, ABAB, BBAA, etc.).

The unit of randomization is the individual participant (individual randomization). Each eligible patient will be independently assigned to one of the two study groups, namely, the cefazolin-only group or the cefazolin-plus-metronidazole group, according to the randomization list.

Randomization will be performed using a randomization list and a randomization table, which will also be used for the preparation of the medication packages.

Generation of the Randomization Sequence

The allocation sequence will be generated using block randomization with blocks of four participants. The order of allocation within each block will be determined randomly (e.g., AABB, ABAB, and BBAA).

Allocation Concealment

To maintain allocation concealment, the study will be conducted using a double-blind design. Medication packages will be prepared in advance according to the randomization table. Each package will contain two syringes of identical volume and appearance. In the control group, the second syringe will contain normal saline, whereas in the intervention group, it will contain 500 mg of metronidazole.

The surgical team and outcome assessors will receive only the package number and will remain unaware of the actual contents of the medications and group assignments. Only the individual responsible for preparing the medication packages will have access to the group allocation information. The allocation code will be disclosed only in emergency situations, Blinding description: This study will be conducted as a double-blind randomized clinical trial. After block randomization, pre-prepared and numbered medication packages will be used. Each package will contain two syringes with identical appearance and volume. In the intervention group, the second syringe will contain metronidazole 500 mg IV, while in the control group, the second syringe will contain normal saline as placebo. Cefazolin will be administered according to the study protocol in both groups before surgery.

The patients, surgeons, operating room staff, and outcome assessors will be blinded to the allocated treatment group. Medication preparation and coding will be performed by an independent person who is not involved in patient care or outcome assessment. The randomization code will only be opened in case of an emergency when knowledge of the treatment allocation is medically necessary.</study_design>
      <phase>3</phase>
      <hc_freetext>Surgical Site Infection (SSI)Surgical Wound InfectionPostoperative Urinary Tract Infection (UTI)Vaginal Cuff Infection after HysterectomyUterine Leiomyoma (Uterine Fibroid)Abnormal Uterine Bleeding (AUB).</hc_freetext>
      <i_freetext>Intervention 1: Participants allocated to the intervention group will receive a single dose of intravenous cefazolin (2 g) in combination with intravenous metronidazole (500 mg), 30 minutes before the start of surgery. The medications used will be manufactured by Abidi Pharmaceutical Company. Both drugs will be administered intravenously by an anesthesiologist. This intervention is intended to prevent surgical site infections in women undergoing abdominal hysterectomy or abdominal myomectomy. The medications will be administered as a single preoperative dose. Both patients and the surgical team will be blinded to the type of medication received. Intervention 2: **Control Group:** Participants allocated to the control group will receive a single dose of intravenous cefazolin (2 g), 30 minutes before the start of surgery. The medication will be manufactured by Abidi Pharmaceutical Company. Cefazolin will be administered intravenously by an anesthesiologist for the prevention of surgical site infections in women undergoing abdominal hysterectomy or abdominal myomectomy. Metronidazole will not be administered in this group. Cefazolin will be given as a single preoperative dose. Both patients and the surgical team will be blinded to the type of medication received.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is due to the need to protect participants confidentiality and privacy and as the study data include individual clinical information of patients individual participant data will not be shared outside the research team.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>shokouh mollaei zamani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>North Kargar Street, Jalal Al Ahmad Avenue intersection, Tehran, Iran</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713135</zip>
        <telephone>+98 21 4437 4789</telephone>
        <email>sh_molaeezamani@razi.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>shokouh mollaei zamani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>North Kargar Street, Jalal Al Ahmad Avenue intersection, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713135</zip>
        <telephone>+98 21 4437 4789</telephone>
        <email>sh_molaeezamani@razi.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>age &gt;18 &amp; BMI &lt;30</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Women who had received antibiotics within the previous 14 days.
Women older than 60 years.
Women with a preoperative infection.
Women with preoperative fever
Women with immunodeficiency.
Women receiving immunosuppressive therapy.
Women with a history of radiotherapy.
Women with a known allergy to penicillin.
Women with a known allergy to cephalosporins.
Women taking corticosteroids.
Women with diabetes mellitus.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Participants allocated to the intervention group will receive a single dose of intravenous cefazolin (2 g) in combination with intravenous metronidazole (500 mg), 30 minutes before the start of surgery. The medications used will be manufactured by Abidi Pharmaceutical Company. Both drugs will be administered intravenously by an anesthesiologist. This intervention is intended to prevent surgical site infections in women undergoing abdominal hysterectomy or abdominal myomectomy. The medications will be administered as a single preoperative dose. Both patients and the surgical team will be blinded to the type of medication received.</i_keyword>
      <i_keyword>**Control Group:** Participants allocated to the control group will receive a single dose of intravenous cefazolin (2 g), 30 minutes before the start of surgery. The medication will be manufactured by Abidi Pharmaceutical Company. Cefazolin will be administered intravenously by an anesthesiologist for the prevention of surgical site infections in women undergoing abdominal hysterectomy or abdominal myomectomy. Metronidazole will not be administered in this group. Cefazolin will be given as a single preoperative dose. Both patients and the surgical team will be blinded to the type of medication received.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Ncidence of surgical site infection (SSI) within 14 days after abdominal hysterectomy or myomectomy. Timepoint: The primary outcome (surgical site infection, SSI) will be assessed during the 14-day postoperative follow-up period. Evaluation will include the occurrence of surgical wound infection, urinary tract infection, and vaginal cuff infection after surgery. Method of measurement: The primary outcome will be assessed by clinical examination performed by the research physician evaluation of signs and symptoms of surgical wound infection, examination of the abdominal incision site, vaginal examination for assessment of vaginal cuff infection, evaluation of urinary tract infection symptoms, and recording of vital signs including fever during the 14-day postoperative follow-up period.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Occurrence of postoperative febrile complications. Timepoint: Assessed and recorded during the 14-day postoperative follow-up period. Method of measurement: Assessed by measuring body temperature and monitoring vital signs during hospitalization and postoperative follow-up.</sec_outcome>
      <sec_outcome>Duration of surgery. Timepoint: Measured and recorded from the beginning to the end of surgery. Method of measurement: Calculated using the recorded operation start and end times documented in the anesthesia or operative report.</sec_outcome>
      <sec_outcome>Length of hospital stay after surgery. Timepoint: Recorded from postoperative admission until hospital discharge. Method of measurement: Calculated in days based on the admission and discharge dates and times recorded in the patient's medical records.</sec_outcome>
      <sec_outcome>Need for blood transfusion during or after surgery. Timepoint: Assessed and recorded during surgery and the postoperative hospitalization period. Method of measurement: The occurrence of blood transfusion will be recorded based on the operative report, anesthesia records, and medical records.</sec_outcome>
      <sec_outcome>Requirement for additional postoperative antibiotic therapy. Timepoint: Assessed and recorded during the 14-day postoperative follow-up period. Method of measurement: The need for additional antibiotic therapy will be recorded based on physician prescriptions and review of medication and medical records.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-11-09</approval_date>
        <contact_name>Ethics committee of Tehrna University of Medical Sciences</contact_name>
        <contact_address>No. 100, Qods Street, Enghelab Avenue, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
